Replies to post #188252 on Biotech Values

[willyw]

To anybody:
I'm not sure I saw a link to the AM webcast/presentation.
I don't see one at ENTA currently, whereas I should think it would be archived.

Anyone got a link or directions?

[zipjet]

>>I interpret this to mean that the FXR target of ENTA’s preclinical drug has been “validated” by ICPT’s OCA; hence, if ENTA’s drug is somehow better than OCA, it could end up being a significant asset.

That would be a great reason to buy ENTA, IMO.

[dewophile]

ENTA NASH

They have more potent agents, but are there good preclinical models to assess efficacy for NASH?

an interesting development would be a cylophilin inhibitor for liver fibrosis that could potentially be used with an FXR - now that would give them a real edge

[mcbio]

ENTA

I interpret this to mean that the FXR target of ENTA’s preclinical drug has been “validated” by ICPT’s OCA; hence, if ENTA’s drug is somehow better than OCA, it could end up being a significant asset.

Has ENTA given guidance as to when they expect their NASH drug(s) to hit the clinic? Also, just curious if they've given any early inkling as to how they could be differentiated from the ICPT drug.